JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

21.11 0.81

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.83

Максимум

21.44

Ключови измерители
By Trading Economics
Приходи	-7.3M -68M
Продажби	23M 68M
Марж на печалбата	-99.318
Служители	298
EBITDA	42M -15M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+88.38% upside

Дивиденти
By Dow Jones
Следващи печалби	30.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	123M 1.9B
Предишно отваряне	20.3
Предишно затваряне	21.11

Настроения в новините

By Acuity

50%

177 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.04.2026 г., 23:33 ч. UTC

Горещи акции

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28.04.2026 г., 23:24 ч. UTC

Печалби

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28.04.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28.04.2026 г., 22:46 ч. UTC

Печалби

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28.04.2026 г., 22:37 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28.04.2026 г., 22:15 ч. UTC

Печалби

Значими събития в новините

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28.04.2026 г., 23:31 ч. UTC

Печалби

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28.04.2026 г., 23:31 ч. UTC

Печалби

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28.04.2026 г., 23:30 ч. UTC

Печалби

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28.04.2026 г., 23:30 ч. UTC

Печалби

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28.04.2026 г., 23:19 ч. UTC

Пазарно говорене

Печалби

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28.04.2026 г., 23:09 ч. UTC

Печалби

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28.04.2026 г., 23:03 ч. UTC

Пазарно говорене

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees One Rate Rise to 4% in Benign Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28.04.2026 г., 22:51 ч. UTC

Печалби

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28.04.2026 г., 22:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.04.2026 г., 22:48 ч. UTC

Пазарно говорене

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28.04.2026 г., 22:40 ч. UTC

Пазарно говорене

Значими събития в новините

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28.04.2026 г., 22:32 ч. UTC

Печалби

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28.04.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28.04.2026 г., 22:22 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28.04.2026 г., 22:17 ч. UTC

Пазарно говорене

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28.04.2026 г., 22:14 ч. UTC

Печалби

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28.04.2026 г., 22:14 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28.04.2026 г., 22:07 ч. UTC

Пазарно говорене

Значими събития в новините

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

88.38% нагоре

12-месечна прогноза

Среден 39.56 USD 88.38%

Висок 57 USD

Нисък 28 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

177 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.